-

Shareholder Alert: The Ademi Firm Investigates Whether LENSAR, Inc. is Obtaining a Fair Price for Its Public Shareholders

MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating LENSAR (NASDAQ: LNSR) for possible breaches of fiduciary duty and other violations of law in its transaction with Alcon.

Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you.

In the transaction, LENSAR shareholders will receive only $14.00 per share in cash (an aggregate implied value of approximately $356 million*), with an additional non-tradeable contingent value right offering up to $2.75 per share in cash, conditioned on achievement of 614,000 cumulative procedures with LENSAR’s products between January 1, 2026, and December 31, 2027. LENSAR insiders will receive substantial benefits as part of change of control arrangements.

The transaction agreement unreasonably limits competing transactions for LENSAR by imposing a significant penalty if LENSAR accepts a competing bid. We are investigating the conduct of the LENSAR board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts

Ademi & Fruchter LLP
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001

Ademi & Fruchter LLP

NASDAQ:LNSR

Release Versions

Contacts

Ademi & Fruchter LLP
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001

More News From Ademi & Fruchter LLP

Shareholder Alert: The Ademi Firm investigates whether Inozyme Pharma, Inc. is obtaining a Fair Price for its Public Shareholders

MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Inozyme (Nasdaq: INZY) for possible breaches of fiduciary duty and other violations of law in its transaction with BioMarin. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, shareholders of Inozyme will receive $4.00 per share in an all-cash transaction for a total consideration...

Shareholder Alert: The Ademi Firm investigates whether Foot Locker, Inc. is obtaining a Fair Price for its Public Shareholders

MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Foot Locker (NYSE: FL) for possible breaches of fiduciary duty and other violations of law in its transaction with DICK’S Sporting Goods. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, shareholders of Foot Locker will receive either (i) $24.00 in cash or (ii) 0.1168 shares of D...

Ademi & Fruchter LLP Continues to Investigate Claims of Securities Fraud against UnitedHealth Group Incorporated

MILWAUKEE--(BUSINESS WIRE)--Ademi & Fruchter LLP is investigating possible securities fraud claims against UnitedHealth (NYSE: UNH). The investigation results from inaccurate statements UnitedHealth made regarding its business operations and prospects. Click here to join our investigation or to obtain additional information, or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. The investigation focuses on UnitedHealth’s recent revisions to...
Back to Newsroom